KPT-330, analog of KPT-185, is an orally bioavailable selective CRM1 inhibitor.

KPT-276, analog of KPT-185, is a CRM1 blocker and acts as an orally bioavailable selective inhibitor of nuclear export (SINE) by irreversibly binding to CRM1.

Verdinexor is an orally bioavailable selective inhibitor of nuclear export (SINE), inhibits nuclear export protein Exportin 1 (XPO1/CRM1) against canine tumor cell lines and also reduce influenza virus replication in vitro and in vivo.

KPT-8602 is a second-generation and oral acitve exportin-1 (XPO1/CRM1) inhibitor with IC50 of 20−211 nM in 10 AML cell lines.

Leptomycin B is an inhibitor of the nuclear export of proteins which acts by binding directly to and inhibiting CRM1/exportin-1. Leptomycin B inhibits the nuclear export of the HIV regulatory protein Rev and stabilizes p53, showing antiviral, antibiotic, antifunal and antitumor in vitro and in vivo.

KPT-185 is a selective CRM1 inhibitor that induces growth inhibition and apoptosis in a panel of NHL cell lines with a median IC50 ~25 nM.

KPT-8602 Z-isomer is an isomer of KPT-8602, which is highly specific for XPO1 inhibition and demonstrates potent anti-leukemic activity.